Related Experiment Video
Updated: Jun 30, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
10.9K
CHIP'ing Signal from Noise in Liquid Biopsy
Elsa Bernard1,2, Jean-Baptiste Micol3,4,5
1INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Summary
Clonal hematopoiesis (CH) in cell-free DNA (cfDNA) can alter results and affect cancer treatment. Distinguishing CH variants from tumor variants is crucial for accurate diagnosis and therapy.
Area of Science:
- Oncology
- Genetics
- Molecular Diagnostics
Background:
- Cell-free DNA (cfDNA) analysis is vital for cancer detection and monitoring.
- Clonal hematopoiesis (CH) is the presence of somatic mutations in hematopoietic stem cells.
- CH variants in cfDNA can be mistaken for tumor-derived mutations.
Purpose of the Study:
- To highlight the challenge of differentiating cfDNA variants originating from CH versus tumors.
- To discuss the clinical implications of misinterpreting cfDNA variant origins.
- To emphasize the need for accurate variant source attribution in clinical practice.
Main Methods:
- Review of current literature on CH and cfDNA analysis.
- Discussion of diagnostic strategies for variant origin determination.
- Analysis of clinical case scenarios illustrating the impact of CH.
Main Results:
- CH variants can lead to false-positive cancer diagnoses or misinterpretations of treatment response.
- Failure to distinguish CH can result in unnecessary treatments or delayed/inappropriate cancer therapies.
- Distinguishing variant origins requires careful consideration of patient history and variant patterns.
Conclusions:
- Accurate identification of cfDNA variant origins (CH vs. tumor) is essential for reliable cancer diagnostics and treatment.
- Clinical guidelines and diagnostic tools are needed to address the impact of CH on cfDNA interpretation.
- Further research is warranted to improve methods for distinguishing CH from tumoral cfDNA.
